Last edition
News about "Marketing Authorization Application "
Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data
Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.
Marketing Authorization Application | 28/07/2026 | By News Bureau
EMA Approves Marketing Authorization Application of Nidlegy
Philogen and Sun Pharmaceutical Industries Ltd. have announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy.
Marketing Authorization Application | 05/07/2024 | By Aishwarya | 521
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy